111 filings
Page 2 of 6
6-K
vn06rz33w 22gno6
28 Mar 23
Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development
8:00am
6-K
qkhkwk
12 Jan 23
Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates
4:30pm
6-K
eo3x2a
10 Nov 22
Current report (foreign)
8:30am
6-K
gho4ncb
7 Nov 22
Assessment showed participants who received a single dose of SLN360 maintained median reductions over 80% over a five-month period
8:30am
6-K
bfkt9
29 Sep 22
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
8:00am
6-K
0fyson2q
16 Aug 22
Current report (foreign)
4:43pm
424B5
895 l9pj9uug
12 Aug 22
Prospectus supplement for primary offering
1:32pm
6-K
of8wotq611
12 Aug 22
Silence Therapeutics Announces Pricing of Underwritten Offering
6:07am
6-K
m8wq4qdk
11 Aug 22
6-K Q2 2022 Quarterly Results
5:02pm
6-K
xyl4ijw3t5pzaql2y
14 Jun 22
Current report (foreign)
5:20pm
6-K
8hc8ju90
16 May 22
Current report (foreign)
8:31am
6-K
66dmehpo
16 May 22
Silence Therapeutics plc Notice of Annual General Meeting
8:30am
6-K
8tjuu31xy
25 Apr 22
Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration
8:31am
6-K
sz1 k8iv7
4 Apr 22
Current report (foreign)
8:31am
6-K
wmee is0dlxj41cc
23 Mar 22
Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501
8:30am
6-K
iee6 xaae
22 Feb 22
Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer
6:52am
6-K
9udr67avc
9 Feb 22
SLN360, an investigational siRNA to reduce risk of Lp(a)-mediated cardiovascular disease, was safe and well tolerated in the study
7:30am
6-K
n20dfs0ydraaw8o
13 Dec 21
Current report (foreign)
6:01am